The Medicare Prescription Drug, Improvement, and Modernization Act envisions a stand-alone prescription drug benefit shaped by market competition. We identify several potential difficulties with implementing such a benefit and highlight aspects of the benefit that may require close regulatory oversight. Our analysis suggests that relatively minor changes in how the benefit is financed could reduce budgetary uncertainty and reduce upward pressure on drug prices.